Letters Section Editor: Robert M. Golub,
MD, Senior Editor.
To the Editor: Dr Yaziji and colleagues1 present a cogent argument for a cost-effective algorithmic
approach to HER-2 testing of breast carcinoma based
on a carefully conducted and executed study of 2963 samples. We would like
to point out several issues not directly addressed in the article or the accompanying
Tubbs RR, Hicks DG. HER-2. JAMA. 2004;292(15):1817-1818. doi:10.1001/jama.292.15.1817-b